| 10.12 -0.23 (-2.22%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.43 | 1-year : | 14.52 |
| Resists | First : | 10.64 | Second : | 12.43 |
| Pivot price | 9.9  |
|||
| Supports | First : | 9.02 | Second : | 8.02 |
| MAs | MA(5) : | 10.23 |
MA(20) : | 9.47 |
| MA(100) : | 7.34 |
MA(250) : | 10.99 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 80.8 |
D(3) : | 83.4 |
| RSI | RSI(14): 66.2 |
|||
| 52-week | High : | 18.87 | Low : | 4.32 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRTA ] has closed below upper band by 34.0%. Bollinger Bands are 24.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.33 - 10.38 | 10.38 - 10.43 |
| Low: | 9.88 - 9.95 | 9.95 - 10.01 |
| Close: | 10 - 10.1 | 10.1 - 10.2 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Tue, 07 Oct 2025
Prothena Corp (PRTA) Sees Raised Price Target by HC Wainwright & Co. | PRTA Stock News - GuruFocus
Thu, 25 Sep 2025
Insiders In Prothena Still Down 30% On US$2.75m Investment - Sahm
Thu, 28 Aug 2025
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference - Business Wire
Wed, 18 Jun 2025
Prothena Announces Corporate Restructuring - Business Wire
Tue, 17 Jun 2025
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) - Yahoo Finance
Mon, 16 Jun 2025
Prothena stock rises on Parkinson's trial update (PRTA:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 4.009e+007 (%) |
| Held by Institutions | 19 (%) |
| Shares Short | 4,060 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.481e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 176.6 % |
| Return on Equity (ttm) | -29.8 % |
| Qtrly Rev. Growth | 1.034e+007 % |
| Gross Profit (p.s.) | 5718 |
| Sales Per Share | -233.31 |
| EBITDA (p.s.) | -8.736e+008 |
| Qtrly Earnings Growth | -5.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -193 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | -0.21 |
| Dividend | 0 |
| Forward Dividend | 3.85e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|